ライフサイエンスコーパス: CRF receptor

1 ated by mechanisms other than the identified CRF receptors.

2 factor (CRF) and CRF-related peptides on two CRF receptors.

3 receptors (GPCRs) known as type-1 and type-2 CRF receptors.

4 sidered to be a second endogenous ligand for CRF receptors.

5 s to neurodegeneration through activation of CRF receptors.

6 sing factor (hCRF) C-terminal 33 residues to CRF receptors.

7 inding of the CRF C-terminus 30 residues, to CRF receptors.

8 a-helical conformation when interacting with CRF receptors.

9 elatively independently of the activation of CRF receptors.

10 nificantly blocking both brain and pituitary CRF receptors.

11 slightly altered by blockade of hypothalamic CRF receptors.

12 and CRF(Glu) neurons were dependent on local CRF receptors.

13 rats and at determining the role of central CRF receptors.

14 ceptor activation and, to a lesser extent on CRF receptors.

15 st of corticotropin (ACTH) releasing factor (CRF) receptors.

16 to greater excitatory synaptic efficacy in a CRF receptor 1 (CRF(1))- and cannabinoid receptor 1 (CB(

17 The CRF receptor 1 (CRF-R1) antagonist, NBI-27914 (50-100 mi

18 endent and requires the downstream action of CRF receptor 1 (CRF-R1), suggesting that dopamine induce

19 We previously demonstrated that CRF receptor 1 (CRF1) neurons comprise a specific compon

20 ctions are mediated through their receptors, CRF receptor 1 (CRFR1) and CRFR2, found throughout the C

21 ment increases Abeta production and triggers CRF receptor 1 (CRFR1) and gamma-secretase internalizati

22 releasing factor binds with high affinity to CRF receptor 1 (CRFR1) and is implicated in stress-relat

23 pin-releasing factor (CRF), as activation of CRF receptor 1 (CRFR1) in the medial nucleus of the cent

24 y, pharmacological experiments revealed that CRF receptor 1 and protein kinase A pathways were newly

25 to (1) determine the effect of the selective CRF receptor 1 antagonist (CRF(1)) GW876008 relative to

26 Consistent with this, the CRF receptor 1 antagonist, antalarmin, prevented swim-st

27 eceptor 2 antagonist astressin-2B, but not a CRF receptor 1 antagonist, reversed the inhibitory effec

28 cally attenuated by systemic pretreatment of CRF receptor 1 or dopamine D1 receptor (D1R) antagonist

29 We showed previously that CRF receptor 1-expressing (CRF1+) neurons in the CeA are

30 asing factor (CRF) exerts its action through CRF receptors 1 and 2 (CRF-R1 and CRF-R2).

31 -protein-coupled receptors of the B1 family, CRF receptors 1 and 2 (CRF-R1 and CRF-R2alpha,beta).

32 The corticotropin-releasing factor (CRF) receptor 1 (CRFR1) is a target for the treatment of

33 dependent on corticotropin-releasing factor (CRF) receptor 1 signaling and an intact hypothalamic-pit

34 ng, which was prevented by antagonism of the CRF receptor-1 (CRF-R1), and was mimicked by CRF-R1 agon

35 relapse, a subsequent experiment found that CRF receptor-1 (CRF1) blockade in the AId similarly redu

36 Development of CRF receptor-1 (CRFr1) antagonists has been a focus of n

37 ctor (CRF) actions at both of its receptors, CRF receptor-1 and CRF receptor-2.

38 g elevations in tryptophan hydroxylase-2 and CRF receptor-1 expression and concordant increases in be

39 by increased corticotropin releasing factor (CRF) receptor-1 expression and signalling, which modulat

40 This effect involves CRF receptor 2 (CRF-R2) and activation of the phospholip

41 However, LS injections of CRF receptor 2 antagonist astressin-2B, but not a CRF re

42 ides similarly modulate maternal defense via CRF receptor 2, and that LS is a critical site for the n

43 ne release are prevented by VTA infusions of CRF-receptor 2 (CRF-R2) but not CRF-R1 antagonists.

44 Mice deficient in CRF receptor-2 (R2KO) were used as a model of maladaptiv

45 at both of its receptors, CRF receptor-1 and CRF receptor-2.

46 of the first extracellular domain (ECD1) of CRF receptor 2beta (CRF-R2beta), free and complexed with

47 nal extracellular domain (ECD1) of the mouse CRF receptor 2beta, which is the major ligand recognitio

48 These data indicate that CRF receptors act in concert to increase the magnitude o

49 The current studies examined whether CRF receptor activation in the PFC modulates cognitive f

50 hese results support a propinquity effect in CRF receptor activation, in which the amino-terminal por

51 lexed to the CRF-BP and thus unavailable for CRF receptor activation.

52 ated actions in the vBNST also require local CRF receptor activation.

53 e effects of corticotropin-releasing factor (CRF) receptor activation and antagonism on intracranial

54 Corticotropin-releasing factor (CRF) receptor activation within the basolateral amygdala

55 Reduced corticotropin releasing factor (CRF) receptor activity and hypothalamic-pituitary-adrena

56 nd defecation) while oCRF(9-33)OH (devoid of CRF receptor affinity) showed neither effects.

57 These results suggest that CRF receptor agonist administration is capable of produc

58 n of anorexia is a well documented effect of CRF receptor agonist administration, the central sites a

59 d for the effects on ICSS of the competitive CRF receptor agonist h/rCRF (0-5.0 microg, i.c.v.), the

60 r agonist h/rCRF (0-5.0 microg, i.c.v.), the CRF receptor agonist urocortin (0-5.0 microg, i.c.v.), a

61 Corticotropin-releasing factor (CRF) receptor agonist and CRF binding-protein (CRF-BP) l

62 In marked contrast to the effects of a CRF-receptor agonist, the CRF-BP ligand inhibitor did no

63 To develop selective CRF receptor agonists, we have scanned the sequence -Gln

64 components of the HPA axis, such as CRF and CRF receptors, along with POMC gene and gene products.

65 g memory via activation of local PKA-coupled CRF receptors, an action associated with robust degradat

66 To further elucidate the roles of both CRF receptors and determine their interaction in behavio

67 However, CRF receptors and neuronal elements are present in many

68 Outside of proestrus, activation of both CRF receptors and neurons in the caudal, but not rostral

69 genetic and pharmacological manipulations of CRF receptors and neurons within the dmPFC of female rat

70 blastoma cell line for functional studies on CRF receptors and suggest that CRF may play a regulatory

71 lting in down-regulation of adenohypophyseal CRF receptors and symptoms of depression and anxiety.

72 ess responses by their interactions with the CRF receptors and the CRF-binding protein (CRF-BP).

73 Urocortin III is selective for type 2 CRF receptors and thus represents another potential endo

74 Using the corticotropin-releasing factor (CRF) receptor and the thrombin receptor as a model, we p

75 strated that corticotropin-releasing factor (CRF) receptors and neurons in caudal dorsomedial PFC (dm

76 ts that release CRF into the VTA, activating CRF receptors, and promoting cocaine use.

77 ut relatively impotent in blocking pituitary CRF receptors; and (2) astressin, inverted question mark

78 Therefore, we investigated the effects of CRF receptor antagonism within the dRN on social anxiety

79 particular, administration of a competitive CRF receptor antagonist [0.2, 1 or 5 microg intracerebro

80 st urocortin (0-5.0 microg, i.c.v.), and the CRF receptor antagonist [D-Phe(12), Nle(21,38), C(alpha)

81 The CRF receptor antagonist [D-Phe12,Nle(21,38)C(a)MeLeu(37)

82 In a third experiment, the CRF receptor antagonist alpha-helical CRF(9-41) administ

83 to the BLA either alone or together with the CRF receptor antagonist alpha-helical CRF(9-41) immediat

84 as blocked by treatment with the competitive CRF receptor antagonist alpha-helical CRF9-41 and with t

85 In addition, the putative CRF receptor antagonist alpha-helical CRF9-41 dose-depen

86 ntral tegmental area (VTA), a site where the CRF receptor antagonist antalarmin prevents the reinstat

87 nificantly reduced following infusion of the CRF receptor antagonist D-Phe CRF((12-41)) into the BNST

88 arena, rats were infused with vehicle or the CRF receptor antagonist d-Phe-CRF((12-41)) (50 or 500 ng

89 lar (1000 ng) injections of the nonselective CRF receptor antagonist D-Phe-CRF(12-41) decreased frust

90 inase B (TrKB) inhibitor k-252a, but not the CRF receptor antagonist D-Phe-CRF(12-41).

91 lly blocked by concurrent treatment with the CRF receptor antagonist D-Phe-CRF(12-41).

92 i.c.v.) was blocked by pretreatment with the CRF receptor antagonist d-PheCRF(12-41) (3.0 microg, i.c

93 t cell-deficient mice and was blocked by the CRF-receptor antagonist, Antalarmin.

94 ely absent after exposure to the competitive CRF receptor antagonists alpha-helical CRF(9-41) or rat/

95 CRF receptor antagonists are very effective in reversing

96 These data suggest that CRF receptor antagonists could provide a potential treat

97 Furthermore, these results imply a role for CRF receptor antagonists in the prevention and treatment

98 ned the effects of two different competitive CRF receptor antagonists on the expression of conditione

99 Two pharmacologically distinct CRF receptors are distributed in different brain regions

100 In contrast, functional pituitary CRF receptors are essential for the ACTH response to the

101 of the amygdala (CeA), despite the fact that CRF receptors are more densely distributed in BLA than i

102 saicin-sensitive primary afferents and brain CRF receptors are part of the pathways and biochemical c

103 hat corticotropin-releasing factor (CRF) and CRF receptors are prominent in the PFC, the cognitive ef

104 Corticotropin-releasing factor (CRF) receptors are found in stress-related regions, incl

105 Because corticotropin-releasing factor (CRF) receptors are implicated, we compared CRF receptor

106 ists for the corticotropin releasing factor (CRF) receptors are new tools to investigate stress-relat

107 nding peptide binding and specificity by the CRF receptors as well as a template for designing potent

108 dent and provides important insight into the CRF receptor-associated circuitry that likely underpins

109 CRF receptor autoradiography was performed in rat tissue

110 agonists of corticotrophin-releasing factor (CRF) receptors bind to the receptor by a two-site mechan

111 The synthesis and CRF receptor binding affinities of several new series of

112 (CRF) receptors are implicated, we compared CRF receptor binding in pre- and postpubertal rats.

113 iographic studies to map the distribution of CRF receptor binding sites in the mouse brain.

114 In each brain area, CRF receptor binding was sexually dimorphic, but no two

115 tor (CRF)-immunoreactive fibers and contains CRF receptor-binding sites, suggesting that endogenous C

116 with biological responses mediated by brain CRF receptors, but relatively impotent in blocking pitui

117 ing protein (CRF-BP), a moiety distinct from CRF receptors, but which is nonetheless capable of bindi

118 irect endogenous mechanism for activation of CRF receptors by new mammalian members of the CRF family

119 These results suggest that the pituitary CRF receptor can discriminate between slightly different

120 s of PFC CRF neurons were dependent on local CRF receptors coupled to protein kinase A.

121 d urocortin 1 (Ucn1), which bind to both the CRF receptors CRF-R1 and CRF-R2, and the urocortins 2 (U

122 Corticotropin-releasing factor (CRF) receptors CRF-R1 and CRF-R2 are differentially dist

123 e Y (NPY), glucocorticoid receptor (GR), and CRF receptor (CRF-R) in selected brain regions.

124 Ucn II binds selectively to the type 2 CRF receptor (CRF-R2), with no appreciable activity on C

125 III is a high-affinity ligand for the type 2 CRF receptor (CRF-R2).

126 proposed as an endogenous ligand for type 2 CRF receptors (CRF-R2).

127 factor (CRF) activates neurons that express CRF receptors (CRF-Rs), we followed the kinetics and dis

128 ve disorders, and have high densities of the CRF receptors CRF1 and CRF2.

129 ow sex differences in the association of the CRF receptor (CRF1) with the Gs protein and beta-arresti

130 The corticotropin-releasing factor (CRF) receptors (CRF1 and CRF2) are crucial mediators of

131 mpared the telencephalic distribution of the CRF receptors, CRF1 and CRF2 , and two of their ligands,

132 wo different corticotropin-releasing factor (CRF) receptors, CRF1 and CRF2, have been identified in r

133 (Ucn 1) with high affinity, thus preventing CRF receptor (CRFR) activation.

134 most of these are lacking or impoverished in CRF receptor (CRFR) expression.

135 ral nucleus of the amygdala (CeA), where the CRF receptor (CRFr) plays an important role in anxiety-

136 d -III signal by activating their receptors, CRF receptors (CRFR)1 and -2, to maintain homeostasis th

137 o estimate CRF overexpression and changes in CRF receptors (CRFr1, CRFr2) and the CRF receptor intern

138 The corticotropin-releasing factor (CRF) receptor CRFR2 is expressed widely in peripheral ti

139 factor (CRF) family, and its cognate type 2 CRF receptor (CRFR2) are highly expressed in skeletal mu

140 The type 2 CRF receptor (Crfr2) marks a subset of LS neurons whose

141 cologic blockade of its receptor, the type 2 CRF receptor (CRFR2), attenuated high but not low glucos

142 ) family, binds with high affinity to type 2 CRF receptors (CRFR2) on cardiomyocytes and confers prot

143 eceptor signaling or compensatory changes in CRF receptor density within these structures.

144 routinely used for the study of transfected CRF receptors do express endogenous CRF1 mRNA with splic

145 Corticotropin-releasing factor (CRF) receptors encoded by two distinct genes have recent

146 Thus, eight CRF receptor-expressing areas displayed eight distinct s

147 Although the cellular distribution of CRF receptor expression has been well characterized at t

148 Both of the characterized members of the CRF receptor family (CRF1 and CRF2), are found in the am

149 The neuroanatomic distribution of this CRF receptor family member is consistent with roles in m

150 data reinforce the importance of the ECD1 of CRF receptors for ligand recognition and raise the inter

151 icotropin-releasing factor (CRF) and altered CRF receptor function.

152 nergic, serotonergic, histamine, opiate, and CRF receptors had no effect, but those for adrenergic an

153 Corticotropin-releasing factor (CRF) receptors have been reported to play a role in toni

154 e basis of ligand-binding specificity in the CRF receptor-hormone system, establish a common mechanis

155 Results demonstrate a critical role of CRF receptors in BNST in stress-induced binge eating in

156 Here, we review the role of CRF receptors in both the brain and the gut as part of k

157 These data show that CRF receptors in CeA and LSMLN synapses exert and mainta

158 activation of pituitary and/or hypothalamic CRF receptors in mediating the stimulatory effect of EtO

159 ctural evidence for a primary involvement of CRF receptors in modulation of the postsynaptic excitabi

160 downregulation and desensitization of cloned CRF receptors in murine fibroblast cells (Ltk-) stably t

161 drive leading to downregulation of pituitary CRF receptors in Neo-A animals.

162 e and accurate available tool for localizing CRF receptors in rodent brain.

163 We also assessed the role of CRF receptors in the bed nucleus of the stria terminalis

164 Meanwhile, blockade of CRF receptors in the caudal dmPFC or globally in the bra

165 Therefore, AT(1) and CRF receptors in the CeA contribute to hemodynamic respo

166 pand the study of the regulation and role of CRF receptors in the CRF system.

167 stems and may also support an involvement of CRF receptors in the development of depression such that

168 NIFICANCE STATEMENT Although the presence of CRF receptors in the dorsal and ventral striatum has bee

169 9, 12-15, 18, 19, 22-26, 28, 31) had k(i) to CRF receptors in the high picomolar and low nanomole ran

170 These results implicate the BNST CRF receptors in the mechanism of coping with stress.

171 in, a novel peptide activating both types of CRF receptors in vitro, but with preferential affinity f

172 Further examination of CRF receptors in vole species may reveal a novel role fo

173 f functional corticotropin-releasing factor (CRF) receptors in IMR-32 neuroblastoma cells.

174 ctivation of corticotropin-releasing factor (CRF) receptors in the caudal dorsomedial PFC (dmPFC) imp

175 xpression of corticotropin-releasing factor (CRF) receptors in the guinea pig enteric nervous system.

176 he levels of corticotropin-releasing factor (CRF) receptors in the serotonergic dorsal raphe nucleus

177 se in Arrb2 than females, suggesting greater CRF receptor internalization.

178 nges in CRF receptors (CRFr1, CRFr2) and the CRF receptor internalizing protein, beta-arrestin2 (Arrb

179 himera in which the N-terminal domain of the CRF receptor is replaced by the amino-terminal 16 residu

180 The CRF receptor is widely expressed across a variety of cel

181 Genetic variance in CRF receptors is linked to altered risk for stress disor

182 ion that contains both CRF-ergic neurons and CRF receptors is the midbrain periaqueductal gray (PAG).

183 isorder, the corticotropin-releasing factor (CRF) receptor is upregulated, particularly in the extend

184 CP-154,526 binds with high affinity to CRF receptors (Ki < 10 nM) and blocks CRF-stimulated ade

185 und that neuropeptide signaling via SEB-3, a CRF receptor-like GPCR, facilitates the development of e

186 ists of the corticotrophin releasing factor (CRF) receptor markedly inhibit experimentally induced ex

187 The results also suggest that CRF receptors may provide novel targets in affective dis

188 calcium activated by postsynaptic Gs-coupled CRF receptors may represent a fundamental mechanism by w

189 fic developmental and physiological roles of CRF receptor mediated pathways.

190 Both corticosterone and central CRF receptors modulate pair bonding in the monogamous pr

191 Inhibition of endogenous CRF receptors or neuronal activity blocked the effects o

192 )) and sauvagine showed some selectivity for CRF receptors other than that responsible for ACTH secre

193 dentify several brain regions with conserved CRF receptor patterns across rodent and primate species,

194 nteresting implications for the evolution of CRF receptor patterns and behavior.

195 brain regions with phylogenetically plastic CRF receptor patterns, and have interesting implications

196 a large group of selective and nonselective CRF receptor peptide agonists will facilitate the develo

197 rn blot analysis of cultured BMEC identified CRF receptor protein; stimulation with CRF, or it struct

198 in 1 and 3, anxiogenic peptides that bind to CRF receptors, reduce maternal aggression in lactating m

199 Corticotropin-releasing factor (CRF) receptors represent one of the primary sites for ne

200 These data support a new model of respective CRF receptor roles in stress-related behavior such that,

201 the first extracellular domain (ECD1) of the CRF receptor(s) comprises the major ligand binding site

202 agonists will facilitate the development of CRF receptor selective drugs.

203 havioral effects may be mediated by enhanced CRF receptor signaling or compensatory changes in CRF re

204 These data indicate that increased CRF receptor signalling within a VTA-IPN-MHb circuit tri

205 As expected, blockade of pituitary CRF receptors significantly blunted EtOH-induced ACTH se

206 and validated as a high-affinity ligand for CRF receptor studies.

207 stigated the functional significance of this CRF receptor subtype in anxiety-like and memory processe

208 The CRF receptor subtype mediating the colonic and gastric m

209 antagonists, administered systemically, and CRF receptor subtype nonspecific antagonists, administer

210 f the present study were to characterize the CRF receptor subtypes (CRF-R1 and -R2) and cellular mech

211 biochemically and pharmacologically distinct CRF receptor subtypes (CRFR1 and CRFR2) have been descri

212 ults indicate a differential role of central CRF receptor subtypes in the colonic stimulatory and gas

213 The concept that multiple CRF receptor subtypes in the DRN facilitate distinct cop

214 v.) on gastric and colonic motility, and the CRF receptor subtypes involved and their role in colonic

215 We investigated the CRF receptor subtypes involved in gastric postoperative

216 Two distinct CRF receptor subtypes, CRFR1 and CRFR2, are thought to m

217 function through interaction with different CRF receptor subtypes.

218 Corticotropin-releasing factor (CRF) receptor subtypes 1 and 2 have been implicated in r

219 ation of two corticotropin-releasing factor (CRF) receptor subtypes.

220 fibers and also contained immunolabeling for CRF receptor, suggesting that c-fos-expressing neurons i

221 administration, the function of DA(1/5) and CRF receptors switched from inhibitory to excitatory.

222 esults show that sex differences pervade the CRF receptor system in juvenile and adult rats, and the

223 prevented by pre-stress administration of a CRF receptor type 1 (CRF(1)) antagonist.

224 for the immediate early gene NGFI-B and for CRF receptor type 1 (CRF-R(1)) in the parvocellular port

225 The differential roles for CRF receptor type 1 (CRF-R1) and CRF-R2 in stress-induce

226 y of serotonin neurotransmission through the CRF receptor type 1 (CRF-R1).

227 nal through the activation of two receptors, CRF receptor type 1 (CRFR1) and type 2 (CRFR2), both of

228 The CRF receptor type 1 (CRFR1) is considered the primary an

229 Last, CRF receptor type 1 (CRFR1) mediated the CRF-induced exc

230 We demonstrate the presence of CRF receptor type 1 (CRFR1) on primary beta cells and sh

231 rsy, however, concerning the contribution of CRF receptor type 1 (CRFR1) to this effect and whether C

232 that were blocked by central infusion of the CRF receptor type 1 antagonist, antalarmin.

233 erging evidence also links the activation of CRF receptors type 1 and type 2 with stress-related alte

234 (NT) of the corticotropin releasing factor (CRF) receptor type 1 (R1) were studied by use of murine

235 atement was blocked by administration of the CRF-receptor type 1 (CRF-R1) antagonist antalarmin (500

236 vation of the serotonergic dorsal raphe, (2) CRF-Receptor type 1 (CRF-R1) in the dorsal raphe, (3) Ur

237 al hydrate-anesthetized rats and the role of CRF receptors using the nonselective CRF(1)/CRF(2) antag

238 The role of pituitary CRF receptors was shown by the ability of i.v. injected

239 The importance of hypothalamic CRF receptors was tested by injecting alpha-hel ant. int

240 that is devoid of intrinsic activity at the CRF receptors, was used as control peptide.

241 Expression levels of CRF receptors were measured in the amygdala nuclei and B

242 omized rats, suggesting that a proportion of CRF receptors were occupied before CRF administration, a

243 ted that, following perinatal high-fat diet, CRF receptors were tonically active at NTS-DMV synapses,

244 Corticotropin-releasing factor (CRF) receptors-which bind the hormone CRF as well as rel

245 light recent advances in the interactions of CRF receptors with other GPCRs and non-GPCR proteins and